Tag:

ADHD

Latest Headlines

Latest Headlines

Adults are now the prime market for ADHD drugs in U.S.

Drugmakers often do pediatric studies of their drugs to broaden the markets. But in the case of drugs for attention deficit and hyperactivity disorder (ADHD) that were primarily developed with children in mind, the market is developing the other way, with more adults now taking the drugs than children.

Shire could use boost from adult ADHD med to hit $10B goal

Shire has said it's targeting $10 billion in sales by 2020, with $3 billion of that coming from its current pipeline. Now, it looks like an ADHD product waiting in the wings could be ready in time to help it get there.

Startup Akili partners with nonprofit Autism Speaks to test video game

Akili Interactive Labs has partnered with the nonprofit Autism Speaks to conduct a clinical trial of its cognitive assessment and personalized treatment video game.

Highland pulls in $25M for night-dosed morning ADHD treatment

Highland Therapeutics, a Toronto-based company with delayed-release technology for ADHD treatment, brought in $25 million to push its lead candidates through mid- and late-stage trials and prepare for commercialization.

Alcobra says its ADHD drug works--as long as you don't compare it to placebo

Alcobra is touting the benefits of its in-development ADHD treatment, saying the drug provided a statistically significant benefit over placebo--but only after the company removed data from four "extreme" responders from its analysis.

Catalent partners up with Cingulate on two ADHD drugs

The recently IPO'd Catalent has signed a deal with biotech Cingulate Therapeutics to help develop a duo of candidates for ADHD, tapping its expertise in crafting controlled-release tablets.

Do teens hear what we hear? FDA aims to find out in study of acne, ADHD ads

Acne remedies and ADHD drugs are big markets for the teen demographic--but how exactly are young consumers interpreting advertisements for these products? A soon-to-launch FDA study aims to find out exactly that.

With patent extension up for grabs, Shire agrees to test Vyvanse in preschoolers

To hear Shire tell it, there aren't many adequate and well-controlled drug studies in preschool-aged children with ADHD. But never fear, the company says: It's agreed to a written request by the FDA to investigate its ADHD drug Vyvanse in children aged 4 to 5, with a potential 6-month exclusivity boost for the drug on the line.

Pfizer, Forest and Lilly dominate top 10 ranking of psych meds

Psychiatric meds have been growth superstars for more than a decade, generating billions for their makers. But generics have flooded the playing field, and save a few select on-patent meds, today's top-selling psych meds, dollarwise, are lowercase copycats, not capital-letter brands.

UPDATED: Novartis recalls some Ritalin over packaging issue

Attention deficit hyperactivity disorder drugs like Ritalin have been on the FDA shortage list for a variety of reasons. Now add to that packaging problems which have led Novartis to recall nearly 22,000 bottles.